Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics

Xeris Pharmaceuticals, Inc. (XERS): $2.11

0.02 (+0.96%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add XERS to Watchlist
Sign Up

XERS Price/Volume Stats

Current price $2.11 52-week high $3.26
Prev. close $2.09 52-week low $1.46
Day low $2.08 Volume 1,559,881
Day high $2.16 Avg. volume 1,896,793
50-day MA $1.99 Dividend yield N/A
200-day MA $2.13 Market Cap 312.82M

XERS Stock Price Chart Interactive Chart >


Xeris Pharmaceuticals, Inc. (XERS) Company Bio


Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.


XERS Latest News Stream


Event/Time News Detail
Loading, please wait...

XERS Latest Social Stream


Loading social stream, please wait...

View Full XERS Social Stream

Latest XERS News From Around the Web

Below are the latest news stories about XERIS BIOPHARMA HOLDINGS INC that investors may wish to consider to help them evaluate XERS as an investment opportunity.

Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CHICAGO, December 27, 2023--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 pm Pacific Time. To access the presentation, please visit "Events"

Yahoo | December 27, 2023

11 High Growth Micro-Cap Stocks to Buy

In this article, we discuss 11 high-growth micro-cap stocks to buy. To skip the detailed analysis and past performance of micro-cap stocks, go directly to the 5 High Growth Micro-cap Stocks to Buy. Shares of small companies with market capitalization usually between $50 to $300 million are considered micro-cap stocks. The risk in these investments […]

Yahoo | December 24, 2023

My Top Small-Cap Stock Pick for 2024 Is a Biotech With a Big Opportunity

It is that time of year when market strategists and pundits roll out their predictions and stock picks for the year ahead. This may be done to extend patent life or to produce a more convenient way to deliver the drug.

Yahoo | December 20, 2023

President & COO of Xeris Biopharma Holdings Picks Up 7.5% More Stock

Even if it's not a huge purchase, we think it was good to see that John Shannon, the President & COO of Xeris Biopharma...

Yahoo | November 20, 2023

Xeris Biopharma CEO unveils game-changing drug innovations and record financial success

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share insights on the company's focus on innovative drug formulation technology after reporting strong third-quarter results.

Yahoo | November 17, 2023

Read More 'XERS' Stories Here

XERS Price Returns

1-mo 4.98%
3-mo 0.48%
6-mo 0.96%
1-year -28.72%
3-year -46.31%
5-year -81.01%
YTD -10.21%
2023 76.69%
2022 -54.61%
2021 -40.45%
2020 -30.21%
2019 -58.53%

Continue Researching XERS

Want to see what other sources are saying about Xeris Pharmaceuticals Inc's financials and stock price? Try the links below:

Xeris Pharmaceuticals Inc (XERS) Stock Price | Nasdaq
Xeris Pharmaceuticals Inc (XERS) Stock Quote, History and News - Yahoo Finance
Xeris Pharmaceuticals Inc (XERS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!